Zogenix, Inc. (NASDAQ:ZGNX) – Investment analysts at William Blair issued their Q1 2019 earnings per share (EPS) estimates for shares of Zogenix in a research report issued to clients and investors on Wednesday. William Blair analyst T. Lugo anticipates that the company will post earnings per share of ($0.91) for the quarter. William Blair also issued estimates for Zogenix’s Q2 2019 earnings at ($0.92) EPS, Q3 2019 earnings at ($0.84) EPS and Q4 2019 earnings at ($0.75) EPS.
Several other research firms have also recently issued reports on ZGNX. Mizuho reiterated a “buy” rating and issued a $51.00 price objective on shares of Zogenix in a research report on Wednesday. Leerink Swann reiterated an “outperform” rating on shares of Zogenix in a research report on Sunday, March 4th. BidaskClub upgraded Zogenix from a “hold” rating to a “buy” rating in a research report on Friday, December 29th. JMP Securities assumed coverage on Zogenix in a research report on Monday, November 27th. They issued an “outperform” rating and a $56.00 price target for the company. Finally, ValuEngine upgraded Zogenix from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $43.33.
Zogenix (NASDAQ:ZGNX) last released its quarterly earnings data on Tuesday, March 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by ($0.17). Zogenix had a negative return on equity of 81.65% and a negative net margin of 309.76%. During the same period in the previous year, the firm posted ($0.95) earnings per share.
In related news, Director Roger Hawley sold 63,203 shares of the stock in a transaction on Monday, December 11th. The stock was sold at an average price of $36.84, for a total transaction of $2,328,398.52. Following the sale, the director now owns 105,575 shares of the company’s stock, valued at $3,889,383. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Bradley S. Galer acquired 1,346 shares of the firm’s stock in a transaction that occurred on Wednesday, December 13th. The shares were bought at an average cost of $36.59 per share, for a total transaction of $49,250.14. The disclosure for this purchase can be found here. Company insiders own 5.00% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Stifel Financial Corp acquired a new stake in shares of Zogenix during the second quarter valued at $175,000. Voya Investment Management LLC boosted its stake in shares of Zogenix by 13.5% during the second quarter. Voya Investment Management LLC now owns 14,147 shares of the company’s stock valued at $205,000 after acquiring an additional 1,686 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Zogenix during the third quarter valued at $226,000. Sterling Capital Management LLC acquired a new stake in shares of Zogenix during the third quarter valued at $237,000. Finally, Alliancebernstein L.P. boosted its stake in shares of Zogenix by 16.3% during the second quarter. Alliancebernstein L.P. now owns 17,812 shares of the company’s stock valued at $258,000 after acquiring an additional 2,500 shares during the last quarter.
ILLEGAL ACTIVITY NOTICE: “Research Analysts Issue Forecasts for Zogenix, Inc.’s Q1 2019 Earnings (ZGNX)” was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3253639/research-analysts-issue-forecasts-for-zogenix-inc-s-q1-2019-earnings-zgnx.html.
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.